There are an estimated 5.4 million people with Alzheimer’s disease (AD) in the United States and this number is expected to increase to 13.2 million by 2050. The lack of an accurate early diagnostic method to detect AD adds significant social and economic costs. Currently, $183 billion is spent yearly on Alzheimer’s associated costs.

A pilot study was set up to detect the presence of blood biomarkers for systemic epigenetic changes utilising the EpiSwitch™ platform technology. The EpiSwitch™ technology identified the presence of valid biomarkers in key signature genes associated with Alzheimer’s disease, including amyloid precursor protein (APP), apolipoprotein E (APOE) and phosphatidylinositol-binding clathrin assembly protein (PICALM).